217 related articles for article (PubMed ID: 2128723)
21. Hybridization to an anti-activated platelet monoclonal antibody enhances fibrinolytic potency on urokinase.
Du L; Yu RR; Hua ZC; Zhu DX; Wu GX; Ruan CG
Sci China B; 1993 Dec; 36(12):1483-9. PubMed ID: 8129836
[TBL] [Abstract][Full Text] [Related]
22. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
[TBL] [Abstract][Full Text] [Related]
23. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
24. The search for the ideal thrombolytic agent.
Verstraete M
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
[TBL] [Abstract][Full Text] [Related]
25. Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
Bos R; Nieuwenhuizen W
Ann N Y Acad Sci; 1992 Dec; 667():428-30. PubMed ID: 1309066
[No Abstract] [Full Text] [Related]
26. New approaches to thrombolytic therapy.
Collen D; Lijnen HR
Arteriosclerosis; 1984; 4(6):579-85. PubMed ID: 6439177
[TBL] [Abstract][Full Text] [Related]
27. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.
Runge MS; Harker LA; Bode C; Ruef J; Kelly AB; Marzec UM; Allen E; Caban R; Shaw SY; Haber E; Hanson SR
Circulation; 1996 Sep; 94(6):1412-22. PubMed ID: 8823001
[TBL] [Abstract][Full Text] [Related]
28. Thrombolytic agents in development.
Verstraete M; Lijnen HR; Collen D
Drugs; 1995 Jul; 50(1):29-42. PubMed ID: 7588087
[TBL] [Abstract][Full Text] [Related]
29. Current developments in thrombolytic therapy using novel plasminogen activators.
Seifried E; Tanswell P
Arzneimittelforschung; 1989 Nov; 39(11):1474-82. PubMed ID: 2695093
[TBL] [Abstract][Full Text] [Related]
30. [The fibrinolytic system and its activators].
Seifried E
Z Gesamte Inn Med; 1993; 48(6-7):272-82. PubMed ID: 8333223
[TBL] [Abstract][Full Text] [Related]
31. Pharmacology of thrombolytic agents. Implications for therapy of coronary artery thrombosis.
Marder VJ
Circulation; 1983 Aug; 68(2 Pt 2):I2-5. PubMed ID: 6683134
[TBL] [Abstract][Full Text] [Related]
32. Nonradical excited oxygen species induce selective thrombolysis in vivo.
Stief TW
Thromb Res; 1991 May; 62(3):147-63. PubMed ID: 1716380
[TBL] [Abstract][Full Text] [Related]
33. A comparative ex vivo study of plasminogen activators and proteases for fibrinolytic activity and side effects in rabbits.
Janik BA; Papaioannou SE
Thromb Haemost; 1977 Feb; 37(1):154-61. PubMed ID: 576512
[TBL] [Abstract][Full Text] [Related]
34. Human urokinase and porcine tissue plasminogen activator. A comparative study of the mechanism of fibrinolysis, and the effect of natural proteinase inhibitors and omega-aminocarboxylic acids.
Thorsen S
Dan Med Bull; 1977 Oct; 24(5):189-206. PubMed ID: 908205
[No Abstract] [Full Text] [Related]
35. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
Singh K; Vézina C
J Med; 1974; 5(6):297-302. PubMed ID: 4528600
[No Abstract] [Full Text] [Related]
36. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E
Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744
[TBL] [Abstract][Full Text] [Related]
37. Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
Trübestein G; Popov S; Wolf H; Welzel D
Haemostasis; 1987; 17(4):238-44. PubMed ID: 2442078
[TBL] [Abstract][Full Text] [Related]
38. Fibrinolytic agents.
Schmitz-Huebner U; van de Loo J
Clin Haematol; 1981 Jun; 10(2):481-96. PubMed ID: 7032785
[No Abstract] [Full Text] [Related]
39. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
Lipinski B; Gurewich V; Hyde E
Thromb Diath Haemorrh; 1975 Sep; 34(1):351. PubMed ID: 1188799
[No Abstract] [Full Text] [Related]
40. Activation of the fibrinolytic system.
Robison AK; Collen D
Cardiol Clin; 1987 Feb; 5(1):13-9. PubMed ID: 3103919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]